Compare ResMed Inc. (RMD) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? ResMed Inc. trades at $196 (market cap $28.81B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.47. The key difference: ResMed Inc. pays a 1.21% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | VEA | |
|---|---|---|
Market Cap | $28.81B | — |
Sector | Health | — |
52-Week High | $293.73 | $72.39 |
52-Week Low | $182.82 | $56.02 |
Enterprise Value | $27.99B | — |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VEA trades at $69.23, down 0.67% with a bearish technical signal from moving averages. The ETF maintains strong institutional interest with recent purchases by Greenwood Gearhart and Bessemer Group. VEA offers exposure to developed international markets with a low 0.03% expense ratio and $304 billion in assets under management, providing diversification benefits amid current market conditions.
VEA presents a compelling international diversification opportunity with cost efficiency and solid institutional backing. Key risks include developed market monetary policy shifts and currency fluctuations. The ETF's valuation discount to US markets and consistent institutional accumulation support long-term positioning despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
